Laninamivir

Laninamivir is an antiviral drug used in the treatment and prevention of influenza viruses. It is a neuraminidase inhibitor, a type of drug that works by blocking the function of the viral neuraminidase protein, thus preventing the virus from spreading inside the body.

Mechanism of Action[edit | edit source]

Laninamivir works by inhibiting the activity of the neuraminidase enzyme found on the surface of influenza viruses. This enzyme is crucial for the virus's ability to spread from infected to uninfected cells. By blocking this enzyme, laninamivir prevents the release of new virus particles, thereby limiting the spread of infection.

Usage[edit | edit source]

Laninamivir is administered via inhalation. It is used for the treatment of influenza A and B viruses in adults and children who are at least 10 years old. It is also used for post-exposure prevention of influenza in people aged 10 years and older.

Side Effects[edit | edit source]

Common side effects of laninamivir include bronchitis, cough, and sinusitis. Serious side effects may include bronchospasm and decreased lung function.

Development and Approval[edit | edit source]

Laninamivir was developed by the Japanese pharmaceutical company Daiichi Sankyo and was approved for use in Japan in 2010. It is not currently approved for use in the United States.